Delving into the Latest Updates on Shenzhen Kehui Intelligent Drug Research Center Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Nervous System Diseases

Other Diseases

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	9
Nervous System Diseases	8
Neoplasms	8
Infectious Diseases	3
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	14
Chemical drugs	2
Biological products	1
Proteolysis-targeting chimeras (PROTAC)	1
AAV based gene therapy	1

Top 5 Target	Count

RIPK1(Receptor-interacting serine/threonine-protein kinase 1)	2
IRAK1 x IRAK4	2
Protein kinases	1
LRRK2(Leucine-rich repeat serine/threonine-protein kinase 2)	1
CDK9(Cyclin-dependent kinase 9)	1

The proposed study is a randomized, double-blind, placebo-controlled single and multiple ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetic, and food effects of ARD-885 Film-coated Tablets in healthy subjects.The entire study includes 3 parts: a single ascending dose study, a multiple ascending dose study, and a food-effect bioavailability study in healthy subjects.

Start Date16 Dec 2024

Sponsor / Collaborator

Shenzhen Kehui Intelligent Drug Research Center Co., Ltd.

CTR20261625

/ Not yet recruitingPhase 2

评价ARD-885治疗中重度活动性类风湿关节炎患者的有效性、安全性的随机、双盲、安慰剂对照、多中心II期临床研究

[Translation] A randomized, double-blind, placebo-controlled, multicenter phase II clinical trial evaluating the efficacy and safety of ARD-885 in patients with moderate to severe active rheumatoid arthritis.

主要目的评价ARD-885用于中至重度活动性类风湿关节炎患者的有效性；评价ARD-885用于中至重度活动性类风湿关节炎患者时剂量与疗效之间的关系（仅适用于IIb期）。次要目的评价ARD-885用于中至重度活动性类风湿关节炎患者的安全性；评价ARD-885对中至重度活动性类风湿关节炎患者外周血中相关炎性生物标志物表达的影响；评价ARD-885在中至重度活动性类风湿关节炎患者中的群体药代动力学特征。

[Translation]

Primary Objectives: Evaluate the efficacy of ARD-885 in patients with moderate to severe active rheumatoid arthritis (RA); Evaluate the dose-efficacy relationship of ARD-885 in patients with moderate to severe active RA (Phase IIb only). Secondary Objectives: Evaluate the safety of ARD-885 in patients with moderate to severe active RA; Evaluate the effect of ARD-885 on the expression of relevant inflammatory biomarkers in peripheral blood of patients with moderate to severe active RA; Evaluate the population pharmacokinetic characteristics of ARD-885 in patients with moderate to severe active RA.

Start Date-

Sponsor / Collaborator

Kehui Zhiyao Biotechnology (Shenzhen) Co., Ltd.

100 Clinical Results associated with Shenzhen Kehui Intelligent Drug Research Center Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shenzhen Kehui Intelligent Drug Research Center Co., Ltd.

Login to view more data

100 Deals associated with Shenzhen Kehui Intelligent Drug Research Center Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shenzhen Kehui Intelligent Drug Research Center Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 May 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

15

2

Preclinical

IND Application

1

Phase 2

Other

6

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

ARD-885 ( IRAK1 x IRAK4 )	Rheumatoid Arthritis More	Phase 2
RIPK1 inhibitors (Artivila) ( RIPK1 )	Inflammation More	Preclinical
Sunrise(Artivila)	Neurodegenerative Diseases More	Preclinical
CN119039379 ( IRAK1 x IRAK4 )Patent Mining	Liver Diseases More	Discovery
WO2024046361 ( RIPK1 )Patent Mining	Digestive System Disorders More	Discovery